Thermo Fisher, HealthVerity Partner to Expand Real-World Data Use in Clinical Research

Under the partnership, Thermo Fisher’s PPD clinical research business will gain enterprise-level access to HealthVerity’s TaXOnomy claims dataset, which includes more than 270 million de-identified patient records across the U.S. healthcare system.

Thermo Fisher Scientific has announced a strategic collaboration with HealthVerity to enhance the use of real-world data (RWD) in clinical research and drug development.

HealthVerity is a Philadelphia-based technology company that operates the largest U.S. ecosystem for Real-World Data (RWD), providing privacy-compliant, interoperable, and linked patient datasets from medical, pharmacy, and lab sources.

The company’s solutions enable pharmaceutical companies, insurers, and government agencies to track comprehensive patient journeys for research, clinical trials, and commercial insights and improve overall patient care.

Under the partnership, Thermo Fisher’s PPD clinical research business will gain enterprise-level access to HealthVerity’s TaXOnomy claims dataset, which includes more than 270 million de-identified patient records across the U.S. healthcare system.

Further, the expanded data access is expected to provide deeper insights into disease prevalence, treatment patterns, and provider activity, supporting improvements in trial feasibility, patient recruitment, and study optimization.

The collaboration is also expected to strengthen real-world evidence (RWE) generation capabilities for biopharma sponsors, along with boosting real-world evidence and health economics and outcomes research (HEOR) capabilities across PPD CorEvitas Clinical Registries and PPD Evidera solutions, enabling faster analytics and broader registry-linked insights.

Commenting on the new partnership, Krishna Cheriath, Vice President, Head of Clinical Research, Digital and AI, Biopharma Services, Thermo Fisher Scientific, said, “This collaboration advances our ability to integrate high-quality, linked healthcare data into clinical development. By utilizing one of the largest integrated healthcare data ecosystems with our AI-enabled analytics, we can generate robust real-world evidence to support our customers across the clinical and post-approval continuum.”

In addition, the collaboration enables access to over 70 curated data sources, including electronic medical records, laboratory data, and speciality datasets. The integration of longitudinal and linked datasets is aimed at enabling more precise site selection and faster study startup timelines.

Earlier this year, the US-based global life science and technology and clinical research company announced a strategic partnership with NVIDIA aimed at integrating NVIDIA’s AI platforms into Thermo Fisher Scientific solutions to scale the automation, improve operational accuracy, and speed of laboratories.

Stay tuned for more such updates on Digital Health News